Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridia cluster XIVa, strain relative of sellimonas intestinalis, live
- Development stage
- Unknown
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
clostridia cluster XIVa, strain relative of sellimonas intestinalis, live is a specific live biotherapeutic bacterial strain developed by Vedanta Biosciences. It belongs to the Clostridia cluster XIVa and is phylogenetically related to the species *Sellimonas intestinalis*. This strain is a key component of **VE303**, a defined bacterial consortium consisting of eight clonal commensal bacterial strains. VE303 is designed to prevent recurrent *Clostridioides difficile* infection (rCDI) by restoring the gut microbiota and establishing colonization resistance. The strain contributes to the consortium's therapeutic effect by competing with *C. difficile* for essential nutrients and producing metabolites, such as short-chain fatty acids and secondary bile acids, which inhibit the germination and vegetative growth of the pathogen. It is administered orally in capsule form as part of the VE303 consortium, which is currently in Phase 3 clinical development.
- Other names
- Sellimonas intestinalis strainClostridia cluster XIVa strainVE303 component strainVE-303 component strainVE 303 component strain
Beyond the preview
Go deeper on clostridia cluster XIVa, strain relative of sellimonas intestinalis, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridia cluster XIVa, strain relative of sellimonas intestinalis, live.